US FDA Commissioner Hahn’s Star Turn: Baptism By Fire Turns Perilous
FDA Commissioner Stephen Hahn was added to the White House's pandemic task force as the outbreak grew, but he remained in a background role. That all changed the morning of 18 March, when President Trump tweeted: “I will be having a news conference today to discuss very important news from the FDA concerning the Chinese Virus!” A day later, Hahn was standing with Trump at the podium for the now-daily press briefings on Covid-19.
You may also be interested in...
Efficacy trials are under way and one supplier already has said it would restart production to meet the anticipated demand.
Every new FDA commissioner faces a challenge earning credibility with Congress and the public, but in the context of COVID-19, Stephen Hahn has a double challenge of a public health crisis – and the ongoing prominence of his predecessor at the agency.
The FDA is curiously not one of the HHS entities coordinating the US response to the outbreak, but must monitor for manufacturing disruptions and shortages, as well as approve new treatments and diagnostics.